| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
|
Purity: ≥98%
Artemether (SM224) is a natural product approved as an antimalarial for the treatment of resistant strains of falciparum malaria. Artemether effectively kills both malarial parasites P. falciparum and P. vivax. Artemether is usually used in combination with Lumefantrine for the treatment of malaria. Arthemether also kills trematodes of the species Schistosoma, providing protection against schistosomiasis. Sesquiterpene lactones like artemether, artesunate, and artemisinin have potential applications in certain types of cancer and inflammatory conditions.
| Targets |
Plasmodium
|
|---|---|
| ln Vitro |
Rat C6 glioma cell growth is inhibited by artemeether (0-200 μg/mL, 24-72 h) in a dose- and time-dependent manner[2].
Artemether (0-10 μM, 72 h) suppresses the expression of genes related to osteoclast formation (osteoclast precursor cells, BMMs) caused by RANKL (TRAP, NFATc1, V-ATPase-d2, CTSK, DC-STAMP, MMP-9)[2].
Artemether (48 or 96 h) inhibits the proliferation of BALB/c splenocytes induced by ConA or alloantigen (IC50: 6.3 and 3.5 μM)[4]. In BALB/c splenocytes, artemeether (0-50 μM, 16–36 h) suppresses IL-2 and IFN-γ production[4]. Artemether (0-50 μM, 72 h) inhibits cell cycle progression through G1/S transition, as well as ConA-induced splenocyte, CD4+T, and CD8+ T-cell divisions[4]. |
| ln Vivo |
In SD rats containing C6 glioma cells, artemeether (0-66 mg/kg, p.o.) inhibits tumor growth and angiogenesis[2].
Mice treated with esters (10 mg/kg, i.p., for 8 days) are shielded from LPS-induced osteolytic bone loss[3]. In the DNFB-induced DTH model in BALB/c mice, artemeether (50 and 100 mg/kg, p.o.) inhibits T-cell-mediated immune responses (ear swelling)[4]. |
| Cell Assay |
Cell Line: ConA-stimulated T lymphocytes
Concentration: 1, 10 and 50 μM Incubation Time: 72 h Result: Arrested 47, 56 and 91% (at 1, 10 and 50 μM) of the cells at G0/G1 phases, respectively. |
| Animal Protocol |
Animal Model: LPS (5 mg/kg) treated mice[3]
Dosage: 10 mg/kg Administration: i.p., 8 days Result: prevented the loss of osteolytic bone and the decrease in bone volume caused by LPS. reduced osteoclast surface/bone surface (Oc.S/BS), increased bone volume/total volume (BV/TV), and number of TRAP-positive cells. |
| References |
|
| Molecular Formula |
C16H26O5
|
|---|---|
| Molecular Weight |
298.3746
|
| Exact Mass |
298.18
|
| Elemental Analysis |
C, 64.41; H, 8.78; O, 26.81
|
| CAS # |
71963-77-4
|
| Related CAS # |
Artemether-d3;93787-85-0
|
| Appearance |
Solid powder
|
| SMILES |
C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OC)C
|
| InChi Key |
SXYIRMFQILZOAM-HVNFFKDJSA-N
|
| InChi Code |
InChI=1S/C16H26O5/c1-9-5-6-12-10(2)13(17-4)18-14-16(12)11(9)7-8-15(3,19-14)20-21-16/h9-14H,5-8H2,1-4H3/t9-,10-,11+,12+,13+,14-,15-,16-/m1/s1
|
| Chemical Name |
(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin
|
| Synonyms |
Dihydroqinghaosu methyl ether; Dihydroartemisinin methyl ether; SM224; SM-224; Artemos; Artenam; Artesaph; Artesian; Dihydroartemisinin Methyl Ether; Falcidol; Gvither; Larither; Malartem; SM 224; β-Artemether; β-Dihydroartemisinin Methyl Ether
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 60~100 mg/mL ( 201.09~335.15 mM )
Ethanol : ~60 mg/mL H2O : ~0.1 mg/mL (~0.34 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.38 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.38 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.38 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 3% DMSO + 97% Corn oil: 6mg/ml (20.11mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3515 mL | 16.7577 mL | 33.5154 mL | |
| 5 mM | 0.6703 mL | 3.3515 mL | 6.7031 mL | |
| 10 mM | 0.3352 mL | 1.6758 mL | 3.3515 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
